Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Delayed Data from NSDQ)

$7.89 USD

7.89
1,606,715

+0.10 (1.28%)

Updated Apr 16, 2024 03:53 PM ET

After-Market: $7.89 0.00 (0.00%) 5:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Ironwood (IRWD) Q3 Earnings Beat on Solid Linzess Sales

Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter.

Ironwood Pharmaceuticals (IRWD) Tops Q3 Earnings and Revenue Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of 64.29% and 10.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jazz Pharma's Xywav Succeeds in Idiopathic Hypersomnia Study

Jazz Pharmaceuticals (JAZZ) posts favorable top-line results from a phase III study on Xywav oral solution, which is being evaluated to treat adult patients with idiopathic hypersomnia. Shares rise.

Ironwood to End IW-3718 Development After Study Failure

Ironwood's (IRWD) pipeline candidate, IW-3718, fails to meet primary endpoint in a phase III study evaluating it in patients with refractory GERD.

Heron's (HRTX) Pain Drug Zynrelef Gets EU Approval, Shares Up

Heron's (HRTX) Zynrelef gains a marketing nod from the European Commission for managing postoperative pain in surgical wounds among adult patients. Stock rises.

Pacira (PCRX) Gains Positive CHMP Opinion for Exparel in EU

The CHMP gives a positive opinion recommending an approval for Pacira's (PCRX) Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.

Why Is Ironwood (IRWD) Down 3.1% Since Last Earnings Report?

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Surging Earnings Estimates Signal Upside for Ironwood (IRWD) Stock

Ironwood (IRWD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Ironwood (IRWD) Q2 Earnings Beat on Solid Linzess Sales

Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. COVID-19 impacts enrollment in clinical studies.

Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of 100.00% and 6.89%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Reports Next Week: What You Should Expect

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Ironwood (IRWD) Down 3.6% Since Last Earnings Report?

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More

The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.

Ironwood Pharmaceuticals (IRWD) Looks Good: Stock Adds 7.6% in Session

Ironwood Pharmaceuticals (IRWD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Ironwood to Halt MD-7246 Development After Study Failure

Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.

Ironwood (IRWD) Misses Q1 Earnings and Revenue Estimates

Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. COVID-19 impacts enrollment in clinical studies.

Ironwood Pharmaceuticals (IRWD) Misses Q1 Earnings and Revenue Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of -63.64% and -7.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Ironwood (IRWD) Keep the Earnings Surprise Streak Alive?

Ironwood (IRWD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Ironwood (IRWD) Down 22.1% Since Last Earnings Report: Can It Rebound?

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ironwood (IRWD) Surpasses Q4 Earnings and Sales Estimates

Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter as well. Stock up.

Ironwood (IRWD) Beats Earnings & Revenues Estimates in Q4

Ironwood Pharmaceuticals (IRWD) reports higher-than-expected earnings and revenues in the fourth quarter.

What's in Store for Ironwood (IRWD) This Earnings Season?

Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.